368 results on '"Lønning, Per E."'
Search Results
2. Demystifying BRAF Mutation Status in Colorectal Liver Metastases: A Multi-institutional, Collaborative Approach to 6 Open Clinical Questions
3. Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy
4. C/EBPB-dependent adaptation to palmitic acid promotes tumor formation in hormone receptor negative breast cancer
5. A national precision cancer medicine implementation initiative for Norway
6. Assessing Novel Therapies Based on Late-Stage Efficacy: A Dangerous Concept?
7. Impact of the APOBEC3A/B deletion polymorphism on risk of ovarian cancer
8. Assessment of tumor suppressor promoter methylation in healthy individuals
9. Supplementary Figure from Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers
10. Supplementary Table from Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers
11. Supplementary Data from A Mitochondrial Target Sequence Polymorphism in Manganese Superoxide Dismutase Predicts Inferior Survival in Breast Cancer Patients Treated with Cyclophosphamide
12. Data from Exploring Breast Cancer Estrogen Disposition: The Basis for Endocrine Manipulation
13. Supplementary Data from Intratumoral Estrogen Disposition in Breast Cancer
14. Supplementary Methods, Figure 1 from Exploring Breast Cancer Estrogen Disposition: The Basis for Endocrine Manipulation
15. Repeated Observation of Breast Tumor Subtypes in Independent Gene Expression Data Sets
16. Microarray Analysis Reveals a Major Direct Role of DNA Copy Number Alteration in the Transcriptional Program of Human Breast Tumors
17. Ineffective Inhibition of Aromatase: A Cause for AI Resistance?
18. APOBEC3A /Bdeletion polymorphism and endometrial cancer risk
19. Constitutional BRCA1 Methylation and Risk of Incident Triple-Negative Breast Cancer and High-grade Serous Ovarian Cancer
20. Demystifying BRAFMutation Status in Colorectal Liver Metastases
21. Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of SDHC
22. NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients
23. Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers
24. White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk
25. APOBEC3A/B deletion polymorphism and endometrial cancer risk.
26. Additional file 1 of Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy
27. Additional file 2 of Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy
28. Additional file 4 of Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy
29. Additional file 3 of Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy
30. SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer
31. The MDM2 Promoter SNP285C/309G Haplotype Diminishes Sp1 Transcription Factor Binding and Reduces Risk for Breast and Ovarian Cancer in Caucasians
32. Polymorphisms in the TP53-MDM2-MDM4-axis in patients with rheumatoid arthritis
33. Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon
34. Impact of MDM2 promoter SNP55 (rs2870820) on risk of endometrial and ovarian cancer
35. Vascular proliferation is a prognostic factor in breast cancer
36. Additional file 2 of Assessment of tumor suppressor promoter methylation in healthy individuals
37. Additional file 3 of Assessment of tumor suppressor promoter methylation in healthy individuals
38. Additional file 5 of Assessment of tumor suppressor promoter methylation in healthy individuals
39. Additional file 1 of Assessment of tumor suppressor promoter methylation in healthy individuals
40. Ri antibodies in patients with breast, ovarian or small cell lung cancer determined by a sensitive immunoprecipitation technique
41. Mutation of GATA3 in human breast tumors
42. C/EBPB-dependent Adaptation to Palmitic Acid Promotes Tumor Formation in Hormone Receptor Negative Breast Cancer
43. Clinical Pharmacokinetics of Aromatase Inhibitors and Inactivators
44. Aromatase Inhibitors and Inactivators for Breast Cancer Therapy
45. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy
46. Molecular portraits of human breast tumours
47. Is There a Growing Role for Endocrine Therapy in the Treatment of Breast Cancer?
48. Recent data on intratumor estrogens in breast cancer
49. Molecular basis for therapy resistance
50. Pharmacological profiles of exemestane and formestane, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.